United Therapeutics Corporation (NASDAQ:UTHR) drug manufacturer, is expected to report second quarter earnings results, before market open, on Wednesday 29th July 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 2.86 per share.
Looking ahead, the full year income are expected at $ 11.72 per share on the revenues of $ 1370.62 million.
Previous Quarter Performance
United Therapeutics Corporation announced income for the first quarter of $ 3.61 per share, from the revenue of $ 356.30 million. The quarterly earnings reduced 31.03 percent while revenues compared with the same quarter last year.
Street analysts expected United Therapeutics Corporation to report income of $ 2.72 per share on revenue of $ 344.33 million for the first quarter. The bottom line results beat street analysts by $ 0.89 or 32.72 percent, at the same time, top line results outshined analysts by $ 11.97 million or 3.48 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of United Therapeutics Corporation
Stock Performance
According to the previous trading day, closing price of UTHR was $ 113.16, representing a 49.72 % increase from the 52 week low of $ 75.58 and a 11.45 % decrease over the 52 week high of $ 127.79.
The company has a market capital of $ 4.98 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”UTHR” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 25th June 2020, maintained by HC Wainwright at Neutral rating, with $ 125.00 target price.
- On 25th June 2020, maintained by Credit Suisse Group at Outperform rating, with $ 145.00 target price.
Conference Call
United Therapeutics Corporation will be hosting a conference call at 9:00 AM eastern time on 29th July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.unither.com
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The companys commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases.
